The pharmacogGENEtics in Youth Depression (GENE-YD) study for personalizing antidepressant pharmacotherapy for young Western Australians - A feasibility study.

Pharmacogenetic test-guided antidepressant prescribing

The GENE-YD study is a triple-blind randomized pilot trial assessing the feasibility of a trial comparing pharmacogenetic-guided antidepressant prescribing with treatment as usual in young people aged 16 to 24 with major depressive disorder in Western Australia. Over 13 months, 73 individuals were screened, 55 were eligible and randomized (1:1), 39 provided baseline data and 38 completed assessments through week 12. Feasibility outcomes — recruitment, adherence, attrition, satisfaction and protocol fidelity — were favorable, with high adherence, low attrition and strong participant satisfaction. The pharmacogenetic-guided group showed greater reductions in depressive symptoms, higher response and remission rates and better quality of life, findings the authors present as preliminary indications of clinical benefit.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The trial shows what it set out to show — a triple-blind protocol is feasible and acceptable in young people with depression — and nothing more: the efficacy signals rest on 38 patients and should not be cited as evidence of benefit. Its value is to prepare an adequately powered trial in an age group where pharmacogenetic data are lacking, while such tests are increasingly available.

Analysis by Dr Thibaut Benquey